AU4730996A - Use of vinyl carboxylic acid compounds for the treatment or prevention of transient ischaemic attacks - Google Patents

Use of vinyl carboxylic acid compounds for the treatment or prevention of transient ischaemic attacks

Info

Publication number
AU4730996A
AU4730996A AU47309/96A AU4730996A AU4730996A AU 4730996 A AU4730996 A AU 4730996A AU 47309/96 A AU47309/96 A AU 47309/96A AU 4730996 A AU4730996 A AU 4730996A AU 4730996 A AU4730996 A AU 4730996A
Authority
AU
Australia
Prior art keywords
prevention
treatment
carboxylic acid
acid compounds
vinyl carboxylic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU47309/96A
Inventor
Kaneyoshi Kato
Takenobu Sohma
Zenichi Terashita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of AU4730996A publication Critical patent/AU4730996A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU47309/96A 1995-02-22 1996-02-21 Use of vinyl carboxylic acid compounds for the treatment or prevention of transient ischaemic attacks Abandoned AU4730996A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP7-33960 1995-02-22
JP3396095 1995-02-22
PCT/JP1996/000394 WO1996025933A2 (en) 1995-02-22 1996-02-21 Use of vinyl carboxylic acid compounds for the treatment or prevention of transient ischaemic attacks

Publications (1)

Publication Number Publication Date
AU4730996A true AU4730996A (en) 1996-09-11

Family

ID=12401068

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47309/96A Abandoned AU4730996A (en) 1995-02-22 1996-02-21 Use of vinyl carboxylic acid compounds for the treatment or prevention of transient ischaemic attacks

Country Status (4)

Country Link
EP (1) EP0810862A2 (en)
AU (1) AU4730996A (en)
CA (1) CA2213507A1 (en)
WO (1) WO1996025933A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242565A1 (en) * 2001-09-11 2004-12-02 Yoshinori Toshima Medicinal composition for prevention of or treatment for cerebrovascular disorder and cardiopathy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0098690B1 (en) * 1982-06-14 1987-09-09 Takeda Chemical Industries, Ltd. Vinyl carboxylic acid derivatives, their production and use

Also Published As

Publication number Publication date
EP0810862A2 (en) 1997-12-10
WO1996025933A2 (en) 1996-08-29
WO1996025933A3 (en) 1996-10-17
CA2213507A1 (en) 1996-08-29

Similar Documents

Publication Publication Date Title
AU2001260400A1 (en) Use of hydrogenotrophic acetogenic strains for preventing or treating digestive disorders
AU7545594A (en) Implantable device for the treatment of aedemas
AU7168696A (en) Inhibitors of regulatory pathways
AU6124996A (en) Certain arylsulfonamido-substituted hydroxamic acids for the treatment of certain tumors
AU698509B2 (en) Compositions for the treatment of rheumatoid-based arthritic diseases
AU1301697A (en) Tyrosin-derivate as alpha-v-integrin inhibitors
AU6956696A (en) Uses of tfpi inhibitor for treatment of cancer
AU6801694A (en) The treatment of small animals
AU1774097A (en) Pharmaceutical compositions for the treatment of rhinitis
AU6232794A (en) The use of nitric oxide-delivering compounds for the treatment or prevention of alcoholic liver injury
AU5563298A (en) Uses of anti-glucocorticoid compounds for the treatment of psychoses or addictive behaviours
AU6106996A (en) Polymers for use as hydrate inhibitors
AU6253094A (en) Methods for the treatment of osteoporosis
AU4136901A (en) Novel methods for the treatment and prevention of dizziness and pruritus
AU8588898A (en) Composition and process for the treatment of epidermal traumas such as decubitusulcers
AU2821295A (en) Compositions and methods for the treatment of tumors
AU3596797A (en) Methods for the treatment of apolipoprotein e related diseases
AU5528996A (en) Methods of treating or preventing pain or nociception
AU6927894A (en) 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions
AUPN380695A0 (en) Methods related to the treatment of and isolation of compounds for treatment of ischaemic conditions
AU5526196A (en) Compositions for the treatment of dandruff
AU4730996A (en) Use of vinyl carboxylic acid compounds for the treatment or prevention of transient ischaemic attacks
AU5699396A (en) Compositions for the treatment of skin conditions
AU1940800A (en) Combination therapy for the treatment of sepsis
AU3902393A (en) Water treatment